CLINICAL RESEARCH: PERIPHERAL AND PULMONARY ARTERY DISEASE
The Novel Phosphodiesterase Inhibitor NM-702 Improves Claudication-Limited Exercise Performance in Patients With Peripheral Arterial Disease
Eric P. Brass, MD, PhD*,*,
Richard Anthony, PhD ,
Frederick R. Cobb, MD ,
Isao Koda, PhD ,
Jenny Jiao, PhD and
William R. Hiatt, MD||
* Department of Medicine, Harbor-UCLA Medical Center, Torrance, California
Catalyst Pharmaceutical Research, Inc., Pasadena, California
Nissan Chemical America, Pasadena, California
Durham VA Medical Center, Durham, North Carolina
|| University of Colorado, Divisions of Geriatrics and Cardiology, and the Colorado Prevention Center, Denver, Colorado
Manuscript received April 12, 2006;
revised manuscript received June 26, 2006,
accepted July 23, 2006.
* Reprint requests and correspondence: Dr. Eric Brass, Harbor-UCLA Medical Center, Center for Clinical Pharmacology, 1124 West Carson, Torrance, California 90502. (Email: ebrass{at}ucla.edu).
OBJECTIVES: The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance.
BACKGROUND: Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited. NM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
METHODS: This study was a randomized, multi-center, placebo-controlled, double-blind trial. Patients were randomized to receive 24 weeks of twice-daily treatment with either placebo (intent to treat population, n = 130), 4 mg NM-702 (n = 126), or 8 mg NM-702 (n = 130).
RESULTS: After 24 weeks of treatment, 8 mg NM-702 was associated with a statistically significant increased peak walking time on a graded treadmill as compared with placebo (p = 0.004). Peak walking time after 24 weeks was increased by 17.1 ± 49.0% in the placebo arm, 22.1 ± 60.1% in the 4-mg NM-702 arm, and 28.1 ± 50.5% in the 8-mg NM-702 arm. NM-702 at the 8-mg dose for 24 weeks was associated with statistically significant improvements in the treadmill claudication onset time as compared with placebo. In addition, as compared with placebo, NM-702 improved the physical component and physical functioning scores of the Medical Outcomes Study 36-Item Short Form and the walking distance and stair climbing domains of the Walking Impairment Questionnaire. NM-702 was generally well tolerated, but adverse events typical of vasodilators were common.
CONCLUSIONS: NM-702 used for 24 weeks by patients with claudication was associated with improvements in laboratory- and ambulatory-based exercise performance.
|
Abbreviations and Acronyms
| | ABI = ankle-brachial index | | ANCOVA = analysis of covariance | | COT = claudication onset time | | NM-702 = 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride | | PAD = peripheral arterial disease | | PWT = peak walking time | | SF-36 = Medical Outcomes Study 36-Item Short Form | | TBI = toe-brachial index | | WIQ = Walking Impairment Questionnaire |
|
This article has been cited by other articles:
|
|
|
|
 
C. M. Wittgen
Limb Ischemia: Medical Therapy Trial Update
Perspectives in Vascular Surgery and Endovascular Therapy,
March 1, 2008;
20(1):
38 - 42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. H. Annex
Is a Simple Biomarker for Peripheral Arterial Disease on the Horizon?
Circulation,
September 18, 2007;
116(12):
1346 - 1348.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Brass, J. Jiao, and W. Hiatt
Optimal assessment of baseline treadmill walking performance in claudication clinical trials
Vascular Medicine,
May 1, 2007;
12(2):
97 - 103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
April 1, 2007;
12(2):
63 - 64.
[Full Text]
[PDF]
|
|
|
|
